ライフサイエンスコーパス: end-stage kidney disease

1 nsion, results in enlarged kidneys and often end stage kidney disease.

2 course of disease, preceding progression to end stage kidney disease.

3 th more frequent remission and less frequent end stage kidney disease.

4 tors are superior to other drugs in reducing end stage kidney disease.

5 ectories were associated with progression to end stage kidney disease.

6 die prematurely than they are to progress to end stage kidney disease.

7 podocyte injury and promotes progression to end-stage kidney disease.

8 ion in the form of AKI, progressive CKD, and end-stage kidney disease.

9 total mortality, nonvascular mortality, and end-stage kidney disease.

10 iovascular adverse events and progression to end-stage kidney disease.

11 protein requirements in patients with CKD or end-stage kidney disease.

12 y 3 wk after birth and progressed rapidly to end-stage kidney disease.

13 patients with atherosclerosis, diabetes, and end-stage kidney disease.

14 o prevent its development and progression to end-stage kidney disease.

15 nd, in steroid-resistant nephrotic syndrome, end-stage kidney disease.

16 causing early-onset nephrotic syndrome with end-stage kidney disease.

17 /min per 1.73 m(2) (stage 3 to 5), excluding end-stage kidney disease.

18 ey transplant for plasma cell dyscrasias and end-stage kidney disease.

19 mated glomerular filtration rate by >=40% or end-stage kidney disease.

20 ow-up of 6.5 years, 1,688 patients developed end-stage kidney disease.

21 pies/mL, and 55% of these patients developed end-stage kidney disease.

22 as the treatment of choice for children with end-stage kidney disease.

23 y ciliopathy and leading cause of hereditary end-stage kidney disease.

24 of morbidity and mortality in patients with end-stage kidney disease.

25 hly prevalent and can eventually progress to end-stage kidney disease.

26 kidney disease (DKD) is the leading cause of end-stage kidney disease.

27 th nephrotic syndrome that often progress to end-stage kidney disease.

28 iatric and adult patients, which can lead to end-stage kidney disease.

29 ffects on glomerular function or the risk of end-stage kidney disease.

30 independently associated with progression to end-stage kidney disease.

31 events and mortality as well as the risk for end-stage kidney disease.

32 ansplantation (KT) is the best treatment for end-stage kidney disease.

33 ion (KT) is the most effective treatment for end-stage kidney disease.

34 ) is the optimal treatment for children with end-stage kidney disease.

35 is the best health option for patients with end-stage kidney disease.

36 diverse and can result in the development of end-stage kidney disease.

37 ansplantation is the preferred treatment for end-stage kidney disease.

38 ogression of chronic kidney disease (CKD) to end-stage kidney disease.

39 disease and one of the most common causes of end-stage kidney disease.

40 decompensated HF, and acute kidney injury or end-stage kidney disease.

41 for type 1 diabetes mellitus and concurrent end-stage kidney disease.

42 despite having the highest global burden of end-stage kidney disease.

43 antation (KT) is the treatment of choice for end-stage kidney disease.

44 The condition introduces a high risk for end-stage kidney disease.

45 0 mL/min/1.73 m2, new-onset albuminuria, and end-stage kidney disease.

46 sistently associated with subsequent risk of end-stage kidney disease.

47 h type 2 diabetes at high risk of developing end-stage kidney disease.

48 ollow-up and information on the incidence of end-stage kidney disease.

49 of renal replacement therapy for those with end-stage kidney disease.

50 eight (LMW) proteinuria that can progress to end-stage kidney disease.

51 rimary outcomes were all-cause mortality and end-stage kidney disease.

52 lly irreversible process causing chronic and end-stage kidney disease.

53 , were the most effective strategies against end-stage kidney disease.

54 hanism to delay the onset and progression of end-stage kidney disease.

55 interstitial fibrosis underlies all forms of end-stage kidney disease.

56 as "myeloma kidney" that often progresses to end-stage kidney diseases.

57 SGLT2 inhibitors also reduced end-stage kidney disease (0.65, 0.53-0.81, p<0.0001), an

58 to 26]), total mortality (9% [-3 to 19]), or end-stage kidney disease (10% [-6 to 23]).

59 Quality of life (13%), mortality (16%), end-stage kidney disease (10%) and cardiovascular events

60 igher as compared with ICU control group non-end-stage kidney disease (25% vs 41.4%; p = 0.005).

61 the following: (1) all-cause mortality; (2) end-stage kidney disease; (3) a decline in estimated glo

62 ronic obstructive pulmonary disease, 3785 of end-stage kidney disease, 579 of cirrhosis, and 6271 of

63 less VVI pacemakers were more likely to have end-stage kidney disease (690 [12.0%] vs 226 [2.3%]; P <

64 tive risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine l

65 Patients with end-stage kidney disease, a reference serum creatinine l

66 ined 30% or more decline in eGFR or reaching end-stage kidney disease, accounting for a potentially r

67 dney disease and the fourth leading cause of end-stage kidney disease, accounting for over 50% of pre

68 sistently associated with subsequent risk of end-stage kidney disease across a range of cohorts, lend

69 its definition (Risk, Injury, Failure, Loss, End-stage kidney disease, Acute Kidney Injury Network, a

70 d 10% of people with lupus nephritis develop end-stage kidney disease after 10 years.

71 The adjusted hazard ratio (HR) for end-stage kidney disease after a 30% decrease in ACR dur

72 imary outcome of interest was development of end-stage kidney disease after a baseline period of 2 ye

73 (AHR, 2.23; 95% CI, 2.14-2.32), dialysis or end-stage kidney disease (AHR, 2.34; 95% CI, 2.24-2.44),

74 sts in Patients With Atrial Fibrillation and End-Stage Kidney Disease), an investigator-initiated PRO

75 a heightened risk of developing chronic and end-stage kidney disease, an association that is largely

76 End stage kidney disease and dialysis are lifetime limit

77 ic uremic syndrome (aHUS) is a rare cause of end-stage kidney disease and associated with poor outcom

78 ing problem across the world and can lead to end-stage kidney disease and cardiovascular disease.

79 rosis and tubular atrophy and progression to end-stage kidney disease and death, respectively.

80 ion may be associated with an excess risk of end-stage kidney disease and death.

81 End-stage kidney disease and dialysis vintage are charac

82 omerulosclerosis (FSGS) is a common cause of end-stage kidney disease and frequently recurs after kid

83 It occurs predominantly in patients with end-stage kidney disease and has high mortality, elusive

84 lication of type 2 diabetes that can lead to end-stage kidney disease and is associated with high car

85 ar calcification is common in the setting of end-stage kidney disease and is associated with increase

86 End-stage kidney disease and serious infections did not

87 review current data on the global burden of end-stage kidney disease and the distribution of major r

88 Data on US patients with end-stage kidney disease and their treatment facilities

89 versies Conference on CAD and CKD (including end-stage kidney disease and transplant recipients) seek

90 E criteria (Risk, Injury, Failure, Loss, and End-stage kidney disease) and assessed using logistic re

91 admissions to hospital for heart failure and end stage kidney disease, and possibly cardiovascular de

92 o dialysis, 7% had progressed to dialysis or end-stage kidney disease, and 7% had been readmitted for

93 ion or died of kidney disease, 335 developed end-stage kidney disease, and 943 had acute kidney injur

94 ), and non-vascular and all-cause mortality, end-stage kidney disease, and adverse events, as well as

95 vascular complications, including blindness, end-stage kidney disease, and amputations.

96 outcomes, including cardiovascular disease, end-stage kidney disease, and death.

97 CVD, stroke, coronary artery disease (CAD), end-stage kidney disease, and mortality using Cox propor

98 SRNS inevitably leads to end-stage kidney disease, and no curative treatment is a

99 Diabetic nephropathy is a major cause of end-stage kidney disease, and overactivity of the endoca

100 diagnosis, 5-20% of patients with LN develop end-stage kidney disease, and the multiple comorbidities

101 enrolled in Medicare Advantage, did not have end-stage kidney disease, and were not institutionalized

102 End-stage kidney disease, as indicated by initiation of

103 factors associated with early progression to end-stage kidney disease assessed by Cox proportional mu

104 significantly associated with lower risk for end-stage kidney disease at week 52 (RR: 0.96: 0.95-0.97

105 SGS), HIV-associated nephropathy (HIVAN) and end-stage kidney disease attributed to hypertension (H-E

106 The growing number of elderly patients with end-stage kidney disease awaiting transplantation has re

107 ant morbidity and mortality to patients with end-stage kidney disease but are resistant to therapy.

108 the optimal treatment for most patients with end-stage kidney disease but organ shortage is a major c

109 y transplantation is the optimal therapy for end-stage kidney disease but requires lifelong immunosup

110 (KT), sexual dysfunction is common owing to end-stage kidney disease, but may improve post-KT.

111 transplant (LDKT) is the ideal treatment for end-stage kidney disease, but racial disparities in LDKT

112 lamines that precede the clinical outcome of end-stage kidney disease by several years.

113 increased risk for post-donation mortality, end-stage kidney disease, cardiovascular disease, non-pr

114 d, PD will be able to permit an expansion of end-stage kidney disease care in these countries.

115 Large numbers of patients with end-stage kidney disease caused by IgA nephropathy are t

116 5 groups of EHMs: chronic kidney disease and end-stage kidney disease (CKD and ESKD), type 2 diabetes

117 Cardiovascular rather than end-stage kidney disease (CKD stage 5) is the leading ca

118 y injury (AKI), and patients with chronic or end-stage kidney disease (CKD/ESKD).

119 lar morbidity and mortality in patients with end-stage kidney disease could be partially caused by ex

120 defined by Risk, Injury, Failure, Loss, and End-stage kidney disease criteria and new need for renal

121 njury, Failure, Loss of kidney function, and End-stage kidney disease criteria for acute kidney injur

122 RIFLE (Risk, Injury, Failure, Loss, End-stage kidney disease) criteria were used to assess s

123 rom baseline; first eGFR <15 mL/min/1.73 m2; end-stage kidney disease; death from kidney causes).

124 nt of ammonia in the breath of patients with end-stage kidney disease demonstrated its significant re

125 sease (DKD) remains the most common cause of end-stage kidney disease despite multifactorial interven

126 =15 mL/min/1.73 m2, dialysis, transplant, or end-stage kidney disease diagnosis), and at least 30%, 4

127 The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or

128 study two variants in APOL1 associated with end-stage kidney disease discovered by admixture mapping

129 208 736 patients who initiated treatment for end-stage kidney disease during 2005-2008.

130 erum creatinine (sustained for >=30 days) or end-stage kidney disease (eGFR <15 mL/min per 1.73 m(2)

131 nors relative to the number of patients with End Stage Kidney Disease (ESKD) has led to prolonged wai

132 Furthermore, adults with end stage kidney disease (ESKD) initiating hemodialysis

133 timated glomerular filtration rate (eGFR) or end stage kidney disease (ESKD) using clinical risk fact

134 with low or low-moderate risk of developing end stage kidney disease (ESKD), and a weak recommendati

135 follow-up and included all-cause mortality, end stage kidney disease (ESKD), serious infections, dis

136 omerulosclerosis (FSGS) is a common cause of end-stage kidney disease (ESKD) across the lifespan.

137 the other hand, are at the increased risk of end-stage kidney disease (ESKD) after donation compared

138 However, burden of end-stage kidney disease (ESKD) after pediatric LT has n

139 The adjusted rate of end-stage kidney disease (ESKD) among African Americans

140 stry to assess adults (aged >=18 years) with end-stage kidney disease (ESKD) and adult KT candidates.

141 Diabetic kidney disease (DKD) can lead to end-stage kidney disease (ESKD) and mortality; however,

142 ary care perspective emphasizing the risk of end-stage kidney disease (ESKD) and need for renal repla

143 to recovery occurred in 4% of patients with end-stage kidney disease (ESKD) and was more common amon

144 k for type 2 diabetic (T2D) and non-diabetic end-stage kidney disease (ESKD) appear strong in African

145 Patients with end-stage kidney disease (ESKD) are at high risk of seve

146 While children approaching end-stage kidney disease (ESKD) are considered at risk o

147 Most children with end-stage kidney disease (ESKD) are treated with dialysi

148 nerenone significantly reduced the hazard of end-stage kidney disease (ESKD) by 20% versus placebo (0

149 The main assigned primary end-stage kidney disease (ESKD) causes was chronic glome

150 Latinx individuals with end-stage kidney disease (ESKD) constitute 19% of US pat

151 y associated with risk of the development of end-stage kidney disease (ESKD) during 10-year follow-up

152 hine learning (ML) in predicting the risk of end-stage kidney disease (ESKD) from patients with chron

153 er, long-term outcomes such as mortality and end-stage kidney disease (ESKD) have been rarely reporte

154 sociation with CKD risk factors and incident end-stage kidney disease (ESKD) in 4,843 participants of

155 Nephronophthisis is a common cause of end-stage kidney disease (ESKD) in children and up to 1%

156 e pathogenesis of DKD and its progression to end-stage kidney disease (ESKD) in humans.

157 It is estimated that >50% of patients with end-stage kidney disease (ESKD) in low-resource countrie

158 y, major adverse cardiac events (MACEs), and end-stage kidney disease (ESKD) in patients with dialysi

159 intraglomerular hemodynamic dysfunction with end-stage kidney disease (ESKD) in people with type 2 di

160 The burden of end-stage kidney disease (ESKD) in sub-Saharan Africa is

161 year following the index hospitalization and end-stage kidney disease (ESKD) in the 10 years followin

162 change using transplant rates normalized to end-stage kidney disease (ESKD) incidence have not been

163 ranging from stage 1 to stage 5 CKD, whereas end-stage kidney disease (ESKD) is defined as permanent

164 End-stage kidney disease (ESKD) is fatal without treatme

165 ents with diabetes and advanced-stage CKD or end-stage kidney disease (ESKD) is not well understood.

166 ncidence of some variation of a composite of end-stage kidney disease (ESKD) outcomes.

167 End-stage kidney disease (ESKD) patients are at high ris

168 End-stage kidney disease (ESKD) patients are living long

169 in in-hospital treatment and outcomes among end-stage kidney disease (ESKD) patients receiving perit

170 Patients with end-stage kidney disease (ESKD) undergoing long-term hem

171 estigated risks of mortality, heart failure, end-stage kidney disease (ESKD), and atherosclerotic car

172 with maintenance dialysis for patients with end-stage kidney disease (ESKD), but it is limited to ap

173 s follows: first-degree relative(s) with CKD/end-stage kidney disease (ESKD), early-onset CKD, focal

174 , depression, chronic kidney disease without end-stage kidney disease (ESKD), ESKD, liver disease, ca

175 to decline in glomerular filtration rate and end-stage kidney disease (ESKD), has been replaced by a

176 nances health care for most US patients with end-stage kidney disease (ESKD), regardless of age.

177 on of proteinuric kidney diseases leading to end-stage kidney disease (ESKD), requiring renal replace

178 es in the hemostatic system in patients with end-stage kidney disease (ESKD).

179 emolytic uremic syndrome (CaHUS) progress to end-stage kidney disease (ESKD).

180 ce is associated with the risk of developing end-stage kidney disease (ESKD).

181 t of increased MA marketing for persons with end-stage kidney disease (ESKD).

182 maternal morbidity including progression to end-stage kidney disease (ESKD).

183 oma (PRCC) is the most common type of RCC in end-stage kidney disease (ESKD).

184 llion people worldwide are being treated for end-stage kidney disease (ESKD).

185 condary outcomes included the development of end-stage kidney disease (ESKD); a composite of a decrea

186 a has been suggested to increase the risk of end-stage kidney disease (ESKD); however, most studies w

187 The increased burden of chronic kidney and end-stage kidney diseases (ESKD) in populations of Afric

188 d the composite clinical endpoint of treated end-stage kidney disease, estimated glomerular filtratio

189 han 1% absolute reduction in 10-year risk of end-stage kidney disease, even at early stages of chroni

190 We defined an end-stage kidney disease event as initiation of kidney r

191 Data for 675 904 individuals and 7461 end-stage kidney disease events were available for our p

192 Cardiovascular (CV) events, end-stage kidney disease events, life years, quality-adj

193 e burden of chronic kidney disease (CKD) and end-stage kidney disease falls disproportionately on Bla

194 nd few or no liver cysts; 8 subjects reached end-stage kidney disease from 62 to 91 years of age.

195 -for-service Medicare receiving dialysis for end-stage kidney disease from January 2017 to November 2

196 Adult patients with incident end-stage kidney disease from the US Renal Data System (

197 sclerosis (FSGS) and hypertension-attributed end-stage kidney disease (H-ESKD) are associated with tw

198 Insurance coverage for patients with end-stage kidney disease has shifted toward more commerc

199 Because patients with advanced CKD and end-stage kidney disease have been excluded from randomi

200 the past 2 decades, while incident rates of end-stage kidney disease have climbed.

201 nsplant waitlisting within the first year of end-stage kidney disease have remained unchanged over th

202 r renal failure to an accepted treatment for end-stage kidney disease, heart disease, liver disease,

203 % CI, 0.43-0.84), and acute kidney injury or end-stage kidney disease (HR, 0.73; 95% CI, 0.57-0.92).

204 any biochemical disturbances associated with end-stage kidney disease improve in the first year after

205 inary tract (CAKUT) are the leading cause of end stage kidney disease in children.

206 on between change in albuminuria and risk of end-stage kidney disease in a large individual participa

207 Although end-stage kidney disease in African Americans (AAs) is f

208 glomerulosclerosis and fibrosis, as well as end-stage kidney disease in children and adults.

209 sease, is the most frequent genetic cause of end-stage kidney disease in children and young adults.

210 Review describes the incidence and causes of end-stage kidney disease in children on long-term dialys

211 leading cause of chronic kidney disease and end-stage kidney disease in children.

212 e in albuminuria as a surrogate endpoint for end-stage kidney disease in clinical trials of progressi

213 Accordingly, the risk of end-stage kidney disease in patients with HFpEF is excep

214 epresents the most frequent genetic cause of end-stage kidney disease in the first three decades of l

215 igher levels of urinary PEDF associated with end-stage kidney disease in the Seattle Kidney Study, wi

216 disease is the leading cause of chronic and end-stage kidney disease in the United States and worldw

217 Most of the 800 000 people living with end-stage kidney disease in the United States rely on a

218 single most common cause of albuminuria and end-stage kidney disease in the United States.

219 e patients has transformed the management of end-stage kidney disease in this population.

220 universal transplantation as the therapy for end-stage kidney disease include the economic limitation

221 Rising numbers of patients reaching end-stage kidney disease intensify the demand for expans

222 End-stage kidney disease is a leading cause of morbidity

223 Treatment for end-stage kidney disease is a major economic challenge a

224 to kidney transplantation for patients with end-stage kidney disease is a national clinical and poli

225 End-stage kidney disease is a significant burden on the

226 guide clinicians in developing comprehensive end-stage kidney disease Life-Plans with hemodialysis ac

227 Among Medicare beneficiaries with end-stage kidney disease, longer intervals between hemod

228 Children with end-stage kidney disease may have coexisting iatrogenic

229 isease, stage 4 or 5 chronic kidney disease, end-stage kidney disease, metastatic cancer, and no bloo

230 CKD and end-stage kidney disease not only increase the risk of C

231 f anticoagulation among patients with AF and end-stage kidney disease on hemodialysis.

232 The primary composite outcome was incident end-stage kidney disease or a 40% decline in estimated g

233 We excluded patients who had end-stage kidney disease or AKI at admission.

234 and incidence of myocardial infarctions, and end-stage kidney disease or kidney failure (moderate to

235 ed period of 8 months to 4 years, subsequent end-stage kidney disease or mortality follow-up data, an

236 lar filtration rate (eGFR) decline, incident end-stage kidney disease, or all-cause mortality over 2

237 idney failure (confirmed 40% eGFR reduction, end-stage kidney disease, or all-cause mortality), and s

238 [or increase in creatinine], progression to end-stage kidney disease, or death attributable to kidne

239 a sustained decline in eGFR of 50% or more, end-stage kidney disease, or death from a kidney disease

240 at least 1 glucose-lowering medication, had end-stage kidney disease, or had stage 5 chronic kidney

241 30 days later) in eGFR by 40%, 50%, or 57%; end-stage kidney disease; or renal death.

242 only results in higher costs but also worse end stage kidney disease outcomes for an already underse

243 eterogeneity and exponential accumulation of end-stage kidney diseases over time prevent long-term pr

244 Data about end-stage kidney disease patients admitted to the ICU ar

245 and to determine the prognostic factors for end-stage kidney disease patients admitted to the ICU.

246 n among 34 857 incident, adult (18-79 years) end-stage kidney disease patients from 690 dialysis faci

247 End-stage kidney disease patients presented frequently s

248 (PBUTs) cause various deleterious effects in end-stage kidney disease patients, because their removal

249 cs, clinical outcomes in SOT recipients, and end-stage kidney disease patients, transplant activity d

250 LDKT provides the best treatment option for end-stage kidney disease patients.

251 n patients with type 1 diabetes mellitus and end-stage kidney disease prevents worsening of diabetic

252 f these RNases were evident in patients with end stage kidney disease prior to PD initiation, and ome

253 heart failure, lower-extremity complication, end-stage kidney disease, proliferative retinopathy, tre

254 In individuals with type 1 diabetes and end-stage kidney disease, PT was associated with an impr

255 research using hard renal endpoints such as end stage kidney disease rather than surrogate markers m

256 Patients with end stage kidney disease receiving in-center hemodialysi

257 aortic valve calcification in patients with end-stage kidney disease receiving hemodialysis in addit

258 to standard therapy, in adult patients with end-stage kidney disease receiving hemodialysis.

259 and serious complication in individuals with end-stage kidney disease receiving peritoneal dialysis.

260 Among US patients with end-stage kidney disease, receiving dialysis at for-prof

261 ng to the US Renal Data System, the national end-stage kidney disease registry.

262 he past few decades, rates of progression to end-stage kidney disease remain high with no beneficial

263 outcomes were kidney events (a composite of end-stage kidney disease, renal death, development of an

264 ine estimated glomerular filtration rate and end stage kidney disease requiring renal replacement the

265 lantation, and 400,000 individuals live with end-stage kidney disease requiring hemodialysis.

266 gher in the Risk, Injury, Failure, Loss, and End-Stage kidney disease (RIFLE) criteria.

267 as meeting Risk, Injury, Failure, Loss, and End-stage kidney disease (RIFLE) Injury or Failure crite

268 here was no detectable effect on the risk of end-stage kidney disease (RR: 0.85; 95% CI: 0.49 to 1.49

269 001) but was not associated with the risk of end-stage kidney disease (SHR, 0.96 [95% CI, 0.62-1.50];

270 failures and adverse kidney outcomes such as end-stage kidney disease, significantly reduced kidney f

271 roved substantially in the past decade, with end-stage kidney disease still developing in 5-30% of pa

272 ency, once established, tends to progress to end-stage kidney disease, suggesting some common mechani

273 s of kidney transplantation as a therapy for end-stage kidney disease that surpasses dialysis treatme

274 For children with end-stage kidney disease, the transplantation of adult-s

275 lerability may be a problem in patients with end-stage kidney disease.The impact of HCV infection on

276 n of modifiable risk factors for chronic and end-stage kidney disease to low- and middle-income count

277 Persons with end-stage kidney disease treated with dialysis experienc

278 es among 346 828 Medicare beneficiaries with end-stage kidney disease treated with hemodialysis who u

279 For patients with end-stage kidney disease treated with hemodialysis, the

280 ve veterans with type 2 diabetes and without end-stage kidney disease treated with metformin who star

281 rt study with 127 AA and white patients with end-stage kidney disease undergoing evaluation for KT (D

282 Most patients with end-stage kidney disease undergoing kidney transplantati

283 entage change in albuminuria with subsequent end-stage kidney disease using Cox regression in each co

284 group; the risk of the composite of death or end-stage kidney disease was 16.9% and 19.6%, respective

285 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio,

286 The incidence of end-stage kidney disease was significantly higher in pat

287 Patients with a faster progression toward end-stage kidney disease were at higher risk of developi

288 938 Hispanic [15.5%]) receiving dialysis for end-stage kidney disease were included.

289 E criteria (risk, injury, failure, loss, and end-stage kidney disease) were employed in identifying c

290 SRNS causes end-stage kidney disease, which cannot be cured.

291 85%, and 69% of patients remained free from end-stage kidney disease, which compares favorably to a

292 of renal significance, face a high burden of end-stage kidney disease, which limits survival and qual

293 timated glomerular filtration rate (eGFR) or end-stage kidney disease, whichever occurred first].

294 ta System Registry to identify patients with end-stage kidney disease who initiated dialysis between

295 tudy in individuals with type 1 diabetes and end-stage kidney disease who underwent PT between 1999 a

296 ommend follow-up and treatment.Patients with end-stage kidney disease without cirrhosis and selected

297 With the rising prevalence of end-stage kidney disease worldwide, the proportion of th

298 isease is among the most important causes of end-stage kidney disease worldwide.

299 l cause of chronic kidney disease leading to end-stage kidney disease worldwide.

300 antation remains the preferred treatment for end-stage kidney disease, yet donor shortages limit its